Clinical Study
Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
Table 4
Annualized bleeding frequency.
| | | Number (%) of patients | | | Prophylaxis
1-2x/wk
() | Prophylaxis
≥3x/wk
() | Total
() |
| | Total bleeds | | | | | 0 | 19 (30.2) | 5 (6.6) | 24 (17.3) | | 0 to 2 | 12 (19.0) | 19 (25.0) | 31 (22.3) | | 2 to 8 | 20 (31.7) | 28 (36.8) | 48 (34.5) | | 8 | 12 (19.0) | 24 (31.6) | 36 (25.9) | | Joint bleeds | | | | | 0 | 25 (39.7) | 13 (17.1) | 38 (27.3) | | 0 to 2 | 18 (28.6) | 23 (30.3) | 41 (29.5) | | 2 to 4 | 10 (15.9) | 12 (15.8) | 22 (15.8) | | 4 | 10 (15.9) | 28 (36.8) | 38 (27.3) |
|
|
